• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Egetis Therapeutics

5.67 SEK

-4.38 %

Less than 1K followers

EGTX

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-4.38 %
-6.59 %
+13.51 %
+6.18 %
+19.12 %
+40.00 %
+14.89 %
+6.73 %
-59.02 %

Egetis Therapeutics is a pharmaceutical company focused on developing innovative treatments for rare diseases. The company researches new therapies that can improve patient outcomes and quality of life. The business has a global presence and serves customers worldwide. Egetis Therapeutics was founded in 2006 and is headquartered in Stockholm, Sweden.

Read more
Market cap
2.78B SEK
Turnover
3.93M SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
21.8.
2026

Interim report Q2'26

6.11.
2026

Interim report Q3'26

All
Webcasts
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Regulatory press release5/29/2026, 8:00 AM

Change in the number of shares and votes in Egetis Therapeutics

Egetis Therapeutics
Press release5/19/2026, 12:00 PM

Egetis to present healthcare resource drivers and cost in MCT8 deficiency at ISPOR 2026

Egetis Therapeutics
Press release5/13/2026, 2:45 PM

Exercise of options under employee stock option program and notification of insider trading

Egetis Therapeutics

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Press release5/7/2026, 8:00 AM

Egetis Therapeutics to Participate in Leading International Medical Conferences in 2026

Egetis Therapeutics
Press release5/5/2026, 6:00 AM

Egetis Announces Grant of Patent for MCT8 Deficiency Composition in the U.S.

Egetis Therapeutics
Press release4/30/2026, 10:30 AM

Egetis Therapeutics to Participate in Pediatric Endocrine Society Annual Meeting 2026

Egetis Therapeutics
Regulatory press release4/30/2026, 7:05 AM

Change in the number of shares and votes in Egetis Therapeutics

Egetis Therapeutics
Egetis Therapeutics, Audiocast, Q1'26
Webcast4/29/2026, 8:00 AM

Egetis Therapeutics, Audiocast, Q1'26

Egetis Therapeutics
Regulatory press release4/29/2026, 5:00 AM

Interim report Q1 2026

Egetis Therapeutics
Press release4/24/2026, 9:00 AM

Invitation to Presentation of Egetis’ First Quarter 2026 Report on April 29, 2026

Egetis Therapeutics
Regulatory press release4/21/2026, 8:57 PM

Egetis Therapeutics has successfully carried out a directed share issue amounting to SEK 350 million (approximately USD 38 million)

Egetis Therapeutics
Regulatory press release4/21/2026, 3:31 PM

Egetis Therapeutics announces the intention to carry out a directed share issue of approximately SEK 350 million (approximately USD 38 million)

Egetis Therapeutics
Regulatory press release4/14/2026, 1:45 PM

Bulletin from Egetis Therapeutics’ Annual General Meeting 2026

Egetis Therapeutics
Press release4/9/2026, 5:00 AM

Egetis Appoints Tiago Nunes as Chief Medical Officer

Egetis Therapeutics
Press release4/8/2026, 11:20 AM

Egetis Receives Conditional FDA Acceptance of Proprietary Name Emcitate®

Egetis Therapeutics
Regulatory press release3/27/2026, 3:42 PM

Egetis Announces FDA Acceptance and Priority Review of NDA for Emcitate® (tiratricol) for MCT8 Deficiency

Egetis Therapeutics
Regulatory press release3/24/2026, 2:05 PM

Egetis Therapeutics’ Annual Report 2025 published

Egetis Therapeutics
Regulatory press release3/12/2026, 11:02 AM

NOTICE OF ANNUAL GENERAL MEETING IN EGETIS THERAPEUTICS AB (PUBL)

Egetis Therapeutics
Press release3/9/2026, 6:00 AM

Egetis Receives Notice of Allowance for MCT8 Deficiency Composition Patent in the U.S.

Egetis Therapeutics
Press release3/5/2026, 9:56 AM

Redeye: Egetis Therapeutics (Q4 review): US approval on the horizon

Egetis Therapeutics